A growing body of evidence from in vitro studies indicates that gap junction proteins connexins (Cx) may have a tumor-suppressor function. Our previous double transfection experiments on HeLa cells have shown that a dominant-negative mutant V139M of Cx32 can abolish gap junctional intercellular communication (GJIC). To examine whether the same dominant-negative mutant of Cx32 inhibits GJIC between hepatocytes in vivo and thus modulates cell proliferation and susceptibility to hepatocarcinogenesis, we created transgenic mice with the mutant Cx32 gene driven by a liver-specific albumin promoter. These mice developed normally both before and after birth, and GJIC in their liver was diminished, as expected. No increase in incidence of spontaneous tumors of any site was observed in the transgenic mice. Rather unexpectedly, cell proliferation during liver regeneration after partial hepatectomy was retarded by 24 hours in the transgenic mice compared with the wild-type mice. In contrast, the transgenic male mice were more susceptible to diethylnitrosamineinduced hepatocarcinogenesis, developing more liver tumors with shorter latency. These results show that GJIC can coordinate cell growth both positively and negatively in vivo, supporting the idea that GJIC is essential for maintenance of homeostasis.
Introduction
The gap junction is a specific type of intercellular junction formed between two adjacent cells and functions as an intercellular channel through which small water-soluble molecules (M r < 1000) passively pass directly from the inside of one cell into neighboring cells. Gap junctions are thus considered to act as a key element in the maintenance of tissue homeostasis (1) . A gap junctional channel consists of two juxtaposed hemichannels (connexons), each provided by one of two adjacent cells. Each connexon is composed of six molecules of the membranespanning connexin (Cx) proteins, encoded by a family of genes consisting of at least 20 members in mammals. The pattern of connexin species expressed differs between tissues and changes during differentiation or development (2) . One cell usually expresses two or more types of connexin protein; for example, both Cx26 and Cx32 are expressed in hepatocytes. The general nature of the molecules that can pass is common to all types of gap junction, but it has been observed that each gap junction may have a relatively specific permeability (3, 4) .
Impaired gap junctional intercellular communication (GJIC) causes various abnormalities, leading to several diseases in human. Many mutations in connexin genes have been reported, such as those in Cx26 in non-syndromic sensorineural deafness (5) and palmoplantar keratoderma (6) , Cx31 in erythrokeratoderma variabilis (7) and hearing impairment (8) , Cx32 in X-linked Charcot-Marie-Tooth disease (9) and Cx50 in zonular pulverulent cataract (10). Most of these mutations are thought to be of a loss-of-function type and some of them are suggested to have dominant-negative characteristics (11). Our laboratory has previously reported that several mutant forms of Cx26, Cx32 and Cx43 inhibit GJIC mediated by their wild-type counterparts in a dominant-negative manner when the mutant and wild-type forms are co-expressed in vitro (12) (13) (14) (15) .
Cancer cells usually display uncontrolled growth and are often GJIC-deficient. While many studies have revealed that enforced expression of connexin in malignant cells restores GJIC and suppresses tumorigenicity (16, 17) , few have addressed the role of gap junctions in growth control by using in vivo systems.
Recent progress in genetic engineering has enabled us to analyze in vivo the function of specific genes by creation of transgenic and/or knock-out mice (18) . Several lines of mice deficient in different connexin genes are currently available and have been used to enrich our knowledge of the biological roles of connexins. However, connexin-deficient mice are not always ideal for studying the role of connexins in carcinogenesis, because the systemic effects of gene disruption often alter the normal function of the organ of interest and may complicate the analysis of carcinogenesis involving local events such as somatic mutations (19) . Moreover, mice lacking the Cx26 and Cx43 genes, both of which are expressed in many tissues, die before and early after birth, respectively (20, 21) . Therefore, we decided to generate transgenic mouse lines in which a dominant-negative mutant Cx32, driven by an albumin promoter, was expressed exclusively in the liver, in order to examine the effect of reduced GJIC on liver carcinogenesis in vivo in the absence of systemic effects caused by disruption of the Cx32 gene, that is expressed widely in the body. In this study, we have established such transgenic mouse lines and have characterized them in terms of cell growth and carcinogenesis in the liver.
Materials and methods

Mice
An XhoI-XbaI fragment isolated from Cx32 V139M/pBluescriptII SK + phagemid (14) containing cDNA for mutant Cx32 V139M (valine to methionine at codon 139) was inserted into the corresponding sites of pGEMAlbSVPA plasmid (22) such that Cx32 V139M would be driven by the albumin promoter. This construct was digested with ApaI and MluI to generate a transgene fragment, which was then transferred into F 2 hybrid zygotes between F 1 hybrids (C57BL/6J × CBA/J) under a contract with the Pasteur Institute (Paris, France).
Founder mice and their offspring were screened by Southern blot and PCR for genotype analysis. Two lines (A and B) of mice expressing the transgene in the liver were finally selected. These lines A and B were then crossed with C57BL/6J mice three times and four times, respectively.
For genotype analysis, 35 cycles of PCR were carried out using the forward primer (5′-GGAAGCCCTATAATGAGACC-3′), recognizing the albumin promoter, and the reverse primer (5′-AAGACTTCTCATCACCCCAC-3′), recognizing the coding region of the Cx32 V139M gene, at 94°C for 30 sec, 55°C for 1 min and 72°C for 1 min. Genomic DNA was isolated from the tail.
Allele-specific RT-PCR
Total RNA was extracted from liver with Trizol Reagent (Life Technologies, Paisley, UK) following the manufacturer's instructions. Extracted RNA was treated with 0.01 U/µl DNase I (Promega, Madison, WI) to eliminate traces of genomic DNA. 5 ng of purified total RNA was transcribed to cDNA primed by random hexaoligonucleotide with MuLV reverse transcriptase (Promega), then subjected to allele-specific PCR to detect transgene-derived cDNA. 25 cycles of PCR were performed using the forward primer (5′- 
Immunostaining of connexin
Fresh liver slices from transgenic or wild-type mice were embedded in 7% gelatin (Sigma), frozen and sectioned in a cryostat (Reichert-Jung, Germany). The 6 µm slices were air-dried, fixed in 10% formalin in PBS for 5 minutes, washed and incubated overnight at 4°C with mono-or polyclonal antibodies against Cx32 (the same as for immunoblotting) or polyclonal antibody against Cx26. A goat anti-rabbit or mouse immunoglobulin antibody conjugated with peroxidase (Sigma) was applied. The reaction was revealed with a solution containing diaminobenzidine, nickel chloride and hydrogen peroxide, and further enhanced by silver development (25) . For immunofluorescence, we followed the previously-described procedure by using the above antibodies against Cx32 (26) and observed the fluorescence-signals under a fluorescence Nikon E-800 microscope (Tokyo, Japan).
Evaluation of the GJIC capacity in liver
To evaluate GJIC capacity, an ex vivo Lucifer yellow dye transfer assay was performed using fresh liver slices from transgenic or wild-type mice, as previously described (27) . In brief, 12 injections of Lucifer yellow CH (Sigma) were performed with a hand-made glass needle into a fresh thin (1 mm) slice of mice liver using an Eppendorf microinjector Model 5242 (Hamburg, Germany). Injected slices were quickly washed in PBS at room temperature, embedded in 7% gelatin (Sigma), frozen and then cut into 6 µm cryosections. Each spot of Lucifer yellow dye spread on serial sections was photographed under a fluorescence Olympus Vannox T microscope (Tokyo, Japan). The areas of Lucifer yellow dye spreading were measured using the NIH image analysis system.
Partial hepatectomy and evaluation of S-phase hepatocytes
To induce liver regeneration, the left liver lobe was surgically removed from the liver of transgenic and wild-type male mice, under anesthesia with ether according to the technique of Higgins and Anderson (28) modified for mice. Five mice each of both genotypes were used per time point.
To evaluate the number of S-phase hepatocytes, groups of transgenic and wild-type male mice received an i.p. injection of 10 mg/kg bw of BrdU (Sigma) 0, 24, 48, 72, 96 or 120 hours after surgery. After one hour of exposure to BrdU, the mice were sacrificed and representative liver slices were fixed in methacarn (60% methanol, 30% chloroform and 10% acetic acid) for 8 to 12 hours for BrdU staining, or embedded in 7% gelatin solution in PBS and frozen for subsequent staining of connexins. Sections were stained for BrdU using antiBrdU monoclonal antibodies (diluted 1:1000, Sigma) and the avidin-biotin-peroxidase system (Dako, CA), revealed by diaminobenzidine. About 3000 hepatocytes were counted in random fields from at least three lobes of each liver, and the percentage of positive nuclei was calculated. (29), was used as a mitogen. TCPOBOP synthesized as described (30) was kindly provided by Mrs Croizy (Paris, France). Male mice aged about 15 weeks received a single dose of 5.8 mg/kg bw TCPOBOP dissolved in corn oil by gavage. Groups of transgenic and wild-type mice were sacrificed at 0, 24, 48 and 72 hours after administration of the mitogen. One hour before killing, each mouse was treated with BrdU as described above. Mice and livers were weighed, and representative liver slices were processed for BrdU immunostatining.
Chemical mitogen-induced proliferation in the liver
Hepatocarcinogenesis
A single dose of 0.9% diethylnitrosamine (DEN) (Sigma) in saline solution was injected intraperitoneally (5 µg/g bw) to groups of 15-day-old males and females of both transgenic and wild-type mice using the protocol described by Vesselinovitch and Mihailovich (31) . The animals were genotyped at 6-8 weeks of age, and divided into four groups. Animals from each group were killed 15, 25, 35 and 49 weeks after DEN treatment. At the time of killing, body and liver weight were recorded for each mouse. Livers were examined for the presence of gross lesions. The lobes were separated and the number and size of superficial lesions were recorded. Internal lesions were counted and measured after preparation of 3-mm sections. Representative slices from standard positions in the liver lobes and those from large liver lesions were collected and fixed in methacarn for histopathological examination. Liver lesions were classified histopathologically according to Harada et al. (32) .
Statistical analysis
For comparison of means of transgenic and wild-type mouse liver parameters, the Student's t test with a 95% confidence interval was applied. For comparison of the multiplicity data in the hepatocarcinogenesis study, a two-way analysis of variance (ANOVA), considering time and genotype as the sources of variation, was performed.
Results
Expression of mutant Cx32 V139M transgene
We have generated two independent lines of transgenic mice. To verify liver-specific expression of the introduced mutant Cx32 V139M gene, allele-specific RT-PCR was performed. While one line (designated as line A) expressed mRNA from the transgene only in the liver as expected ( Figure 1A) , the other (designated as line B) showed strong leaky expression in kidney and brain in addition to the liver ( Figure 1B ). Both lines of mice were used for most of experiments and no difference was found between them. In this paper, only the data from line A are presented.
Since no antibody specific to mutant V139M Cx32 is available, we could not confirm that the expressed mRNA was properly translated to the corresponding protein in the liver of line A. To resolve this problem, we crossed line A mice with Cx32-deficient mice (33) so as to obtain mice in which only the mutant Cx32 V139M was expressed in the liver, without any trace of endogenous wild-type Cx32. As shown in Figure 1C , Cx32 V139M protein was detected in the liver of such a hybrid mouse, indicating that mRNA from the Cx32 V139M construct was indeed translatable in hepatocytes. It has been reported that levels of Cx26 protein are greatly reduced in the liver of Cx32-deficient mice without any decrease in its mRNA (33) . However, our transgenic mice showed a level of Cx26 expression in the liver similar to that of the wild-type counterpart ( Figure 1D ) and Cx26 protein was detected immunohistochemically as plaques at a cell-cell contact area of hepatocytes in mice of both genotypes (Figures 2A and 2B) .
The transgenic mice manifest no abnormal phenotype
We and others previously reported that the mutant Cx32 V139M per se could not be integrated into the plasma membrane (14, 34) . Furthermore, when the mutant Cx32 V139M gene was transfected into wild-type transfected HeLa cells, the numbers of gap junction plaques decreased dependently on the level of expression of the mutant. We therefore suggested that the mutant Cx32 V139M might form non-functional heteromeric complexes with the wild-type Cx32, that might be defective for localization into the plasma membrane of cells (14) .
Our transgenic mouse livers, however, showed a similar pattern of Cx32 in plaques to that in the livers of the wild-type siblings ( Figures 2C and 2D ). Interestingly, while no significant signal was detected in the cytoplasm or nucleus in our transgenic mouse hepatocytes co-expressing both the mutant Cx32 V139M and wild type ( Figure 3E ), the mutant was localized in the nucleus in the absence of the wild type, as revealed by immunofluorescence, in the liver of the hybrid mouse between Cx32-deficient and our transgenic mice ( Figure 3A) . These results suggest that, while the mutant Cx32 V139M per se is incapable of forming gap junctions, it may be able to participate in gap junction plaques in hepatocytes in vivo only in the presence of the wild-type Cx32, whether or not connexons containing the mutant Cx32 are functional.
GJIC capacity is reduced in transgenic mouse liver
In HeLa cells, the mutant Cx32 V139M almost shut off cell-cell communication exerted by the wild type in a dominant-negative manner, as revealed by the Lucifer yellow dye-coupling assay (14) . To examine whether GJIC capacity is reduced in transgenic mouse liver by a dominant-negative effect of the mutant, we measured the cell coupling capacity in the livers of six each of transgenic mice (line A) and wild-type siblings by Lucifer yellow microinjection ( Figure 4A ), as described in Materials and methods. As shown in Figures 4B, GJIC was reduced by 30% in the liver of transgenic mice, confirming that the mutant Cx32 V139M acts in vivo as a dominant-negative inhibitor of wild-type Cx32. This inhibitory effect of the mutant Cx32 was lower than expected, probably because the modestly-expressed mutant protein ( Figure 3A ) may have failed to abolish completely the function of the wild type. Moreover, it is much likely that Cx26 co-expressed with Cx32 in hepatocytes also contributed to such a residual GJIC.
Liver regeneration after partial hepatectomy is delayed in transgenic mice
In quiescent liver of Cx32-deficient mice, the number of S-phase hepatocytes is significantly increased, as measured by bromodeoxyuridine (BrdU) incorporation, compared with wildtype liver, although no gain of liver weight was seen (35) . In contrast, when our transgenic mice and wild-type counterparts were examined by BrdU labelling in the quiescent liver, they both presented a similar percentage of S-phase hepatocytes (data not shown).
We next subjected the animals to partial hepatectomy (resection of the left lobe) to observe the effect of reduced GJIC on hepatocyte proliferation under growth pressure. In the wild-type mouse liver, the hepatocyte BrdU labelling index rose gradually, reaching a 50-fold increase at 48 hours after surgery ( Figures 5A and 5B) . On the other hand, the transgenic mouse liver showed a peak of DNA synthesis 72 hours after surgery ( Figure 5A ). Despite a delay in proliferative response to partial hepatectomy, the transgenic mice were able to complete the process of liver regeneration.
It is well known that expression of both Cx26 and Cx32 in a rat liver is abolished immediately after partial hepatectomy and restored gradually as the regeneration progresses (36) . In the wild-type mice, unlike rats, both Cx26 and Cx32 continued to be expressed only with a slight decline ( Figure 5C ), that was much less drastic than seen in the rat liver. The transgenic mice also showed a similar expression pattern of Cx26 protein to the wild type, indicating that the mutant Cx32 V139M could not modify the expression of Cx26. As shown in Figure 5C , the partially-hepatectomized liver maintained similar levels of albumin, suggesting that the transgene remained activated during liver regeneration. Since the mutant Cx32 V139M is not distinguished from the wild type by the antibody, the expression of Cx32 looks higher in the transgenic mice than the wild-type counterparts ( Figure 5C ).
Transgenic and wild-type livers respond to the mitogen TCPOBOP in a similar manner
The above results suggested that GJIC should play a role in regulation of mitogenic signals triggered by partial hepatectomy. Is GJIC involved in regulation of the signals induced by direct mitogen? In order to estimate whether the delay in proliferative response after a mitogenic stimulus described above is specific to compensatory regeneration or is a common phenomenon associated with cell growth in the liver, we also analyzed the dynamics of proliferative response in liver of transgenic mice versus wild-type mice after treatment with the strong primary liver mitogen TCPOBOP (29) .
A single administration of TCPOBOP induced a progressive gain of liver weight in both transgenic and wild-type mice by 30% during the following 72 hours in a similar manner ( Figure 6A ). No significant difference in BrdU labelling index between the transgenic and wild-type mice was found at any time point ( Figure 6B ). We thus conclude that the delayed G1-S transition observed under conditions of decreased GJIC (Figures 4 and 5A ) is specific to compensatory regeneration induced by partial hepatectomy.
Transgenic mice with mutated Cx32 are not prone to spontaneous liver tumors but have increased susceptibility to DEN-induced hepatocarcinogenesis
To verify whether expression of mutated Cx32 predisposes mice to hepatocarcinogenesis, we first estimated the incidence of spontaneous liver lesions in transgenic mice. Twelve male and thirteen female transgenic mice and five male and six female wild-type mice, aged 13 to 22 months, were necropsied and their livers were examined grossly and histopathologically. Although a few preneoplastic lesions were found in the liver of two transgenic male mice, no liver tumors were found in any of the examined mice.
We next examined whether expression of the transgene increased the susceptibility of mice to chemical hepatocarcinogenesis. Fifteen-day-old transgenic and wild-type mice were given a single i.p. injection of DEN and then kept for 15, 25, 35 or 49 weeks, when groups of them were killed and necropsied and examined for the presence of liver lesions.
At 15 weeks after DEN treatment, no gross lesion was found in the liver of either type of mouse, although a few mice showed microscopically detectable preneoplastic liver lesions (data not shown). Later, at 25, 35 and 49 weeks of experiment, both transgenic and wild-type mice developed liver tumors. Furthermore, the multiplicity of liver tumors (total number of gross lesions / number of mice carrying gross lesions) was higher in transgenic mice of both sexes compared with their wild-type counterparts (Table I ). In addition, at 35 and 49 weeks after DEN treatment, liver lesions (Figure 7 ) in the transgenic mice were larger than in the wild types (Table I) .
Histological examination of liver slices sampled from standard positions revealed that the transgenic male mice had more hepatocellular carcinomas than the wild-type males. Moreover, at the end of the study (49 weeks), the incidence of histologically-diagnosed hepatocellular carcinomas was 42% in the transgenic male mice compared with 14% in the wild-type counterparts (Table II) .
In contrast, female transgenic and wild-type mice developed much fewer preneoplastic or neoplastic lesions than the males and there was no significant difference between the two genotypes in terms of incidence of liver tumors (Tables I and II) .
The two-way analysis of variance (ANOVA) of the multiplicity data, considering genotype and time (weeks) as sources of variation, indicated that both contributed significantly to the observed variance.
Discussion
In this study, to explore the role of Cx32 in growth control of hepatocytes in vivo, we generated transgenic mouse lines in which the mutant Cx32 V139M gene, driven by the albumin promoter, is expressed only in the liver. This approach avoids systemic effects caused by gene disruption, as in gene knock-out models. We have previously reported that the introduced mutant abolishes GJIC exerted by wild-type Cx32 in HeLa cells in a dominantnegative manner, probably due to formation of non-functional heteromeric connexons composed of both wild-type and mutant Cx32 proteins.
Although, as expected, GJIC capacity was reduced in the liver of the transgenic mice ( Figure 4B ), the extent of reduction was much more modest than that seen in HeLa cells (14) . Initially we expected that this mutant would interfere with both Cx32 and Cx26 co-expressed in a hepatocyte because these two types of connexin can form heteromers in vitro (37) . However, our results rather suggest that Cx26 was not affected by the mutant Cx32 V139M in vivo (Figures 2A and 2B ) and that the hepatocytes of the transgenic mice can maintain a moderate level of GJIC due to Cx26 and residual Cx32, that have escaped from the dominantnegative effect of the mutant Cx32. The dominant-negative effect of the V139M mutant of Cx32 may be much less efficient in vivo than in HeLa cells in vitro.
The most remarkable finding in this study was that reduced GJIC in the transgenic liver delayed regeneration after partial hepatectomy ( Figure 5A ). Although the mechanism of triggering of compensatory regeneration of the liver remains controversial and largely unknown, it has been proposed that mitogenic stimuli for hepatocytes appear as humoral factors in the blood shortly after surgery and initiate a chain of events necessary for proliferation of hepatocytes (38) . Such factors exert their effects firstly in periportal hepatocytes, and spread to other zones in the hepatic acinus in a synchronized manner. Correspondingly, hepatocytes start to proliferate in periportal areas, followed by pericentral areas (39) . Thus, such spatial and time-dependent changes during the triggering of liver regeneration may be involving signal transmission at extra-, intra-and intercellular levels. It has indeed been suggested that gap junctions play a role in liver regeneration by spreading second messengers that appear immediately after partial hepatectomy (40) . Reduced GJIC in the liver of the transgenic mice could be responsible for inefficient diffusion of such factors, resulting in the delayed entry of hepatocytes to S-phase.
Our findings with transgenic mice after partial hepatectomy are specific to compensatory regeneration, since treatment with TCPOBOP induced a mitogenic response and primary hyperplasia in the liver of both the transgenic and wild-type mice in a similar manner. TCPOBOP is a liver tumor promoter and categorized as a peroxisome proliferator, which can directly stimulate individual hepatocytes. Thus, it appears that the events modulated by TCPOBOP are downstream to those regulated by gap junctions.
Another important finding in this study was an increased susceptibility of transgenic mice to chemical hepatocarcinogenesis. The transgenic mice displayed not only a higher multiplicity of liver lesions but also a higher incidence of both hepatocellular adenomas and hepatocellular carcinomas, suggesting that reduced GJIC in the transgenic liver facilitated a promotion and progression process during carcinogenesis. This observation is quite consistent with the established idea that cells having no or low GJIC can escape from growth control and gain a growth advantage for clonal expansion (17) .
Our results suggest that GJIC acts positively on cell proliferation during liver regeneration and negatively on tumor development and progression. We have no clear explanation for this apparent contradiction. However, the long-standing idea that gap junctions function to maintain homeostasis of the cellular society suggests that gap junctions transmit certain molecules that are essential for maintaining normal liver volume. Thus, in response to the lack of liver mass after partial hepatectomy, gap junctions play a role in promoting cell growth for regeneration, and once the liver has recovered its original size, the gap junctions may switch their role to normalization of excessive cell growth.
Similarly to our transgenic mice, Cx32-deficient mice manifest higher susceptibility to chemical hepatocarcinogenesis (41, 42) . However, unlike our transgenic mice, they display excessive glycogen storage in the liver and develop neuropathy, similar to Xlinked Charcot-Marie-Tooth disease, due to impaired conductance of sympathetic nerves and atrophy of peripheral nerves, respectively. In addition, mice lacking Cx32 show increased incidence of spontaneous liver tumors and elevated BrdU incorporation even in the quiescent liver. This notable difference in proliferative status of the liver between Cx32 knock-out mice and our transgenic mice could be partly due to a significantly reduced amount of Cx26 protein expressed in the liver of Cx32-deficient mice but not in our transgenic mice ( Figures 1D, 2A and 2B). Cell growth regulation and tumor-suppressive potency of Cx26 have been shown both in vitro and in vivo (43, 44) . These results and our own observations reported here are consistent with the idea that impaired cell coupling disturbs the capacity of a tissue to maintain homeostasis, particularly in response to external cell growth stimuli. Considering that connexins are essential in maintaining homeostasis of various tissues, it is not surprising that connexin gene deletion in mice and connexin gene mutations in humans result in various diseases.
Although numerous studies have provided evidence for growth and tumor suppression by connexins in vitro, our experiments in this study in vivo rather suggest that connexin does not act simply as a growth-suppressor. What we and others have so far observed is that the presence of functional gap junctions nearly always leads cells towards necessary and sufficient growth to maintain proper function of tissues. Since the cell lines often used for in vitro studies are immortalized or even already transformed, it is likely that the function of gap junctions in such cells is to bring the elevated levels of growth down to normal. We now think that gap junctions play a role not only in growth suppression but also in coordinated cell growth, i.e. both positively and negatively to achieve a normal growth rate. Six each of wild-type and transgenic mice were subjected to the assay. 10 slices per mouse were selected randomly and microinjected with LY into 12 sites per slice. *P < 0.05 
